

# Gerard R Dawson

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11459176/gerard-r-dawson-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64  
papers

3,695  
citations

32  
h-index

60  
g-index

67  
ext. papers

3,998  
ext. citations

6.3  
avg, IF

4.52  
L-index

#	Paper	IF	Citations
64	Use of the elevated plus maze in the search for novel anxiolytic agents. <i>Trends in Pharmacological Sciences</i> , <b>1995</b> , 16, 33-6	13.2	399
63	Sedation and anesthesia mediated by distinct GABA(A) receptor isoforms. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 8608-17	6.6	251
62	Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 10682-8	6.6	199
61	Loss of the major GABA(A) receptor subtype in the brain is not lethal in mice. <i>Journal of Neuroscience</i> , <b>2001</b> , 21, 3409-18	6.6	193
60	TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a non-sedating anxiolytic agent. <i>Journal of Medicinal Chemistry</i> , <b>2001</b> , 44, 116-22	4.7	162
59	Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 915-20	11.5	158
58	L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors. <i>Neuropharmacology</i> , <b>2006</b> , 51, 1023-9	5.5	143
57	Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognition. <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 2227-40	8.3	131
56	3-phenyl-6-(2-pyridyl)methoxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding selectivity over alpha 1. <i>Journal of Medicinal Chemistry</i> , <b>2004</b> , 47, 1807-22	8.3	126
55	3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional selectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels. <i>Journal of Medicinal Chemistry</i> , <b>2002</b> , 45, 1887-900	8.3	111
54	Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors. <i>British Journal of Pharmacology</i> , <b>2005</b> , 144, 357-66	8.6	107
53	An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties. <i>Journal of Medicinal Chemistry</i> , <b>2004</b> , 47, 5829-32	8.3	98
52	Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. <i>Neuropharmacology</i> , <b>2007</b> , 53, 810-20	5.5	97
51	Selective, orally active gamma-aminobutyric acid alpha5 receptor inverse agonists as cognition enhancers. <i>Journal of Medicinal Chemistry</i> , <b>2004</b> , 47, 2176-9	8.3	92
50	Fearfulness and sex in F2 Roman rats: males display more fear though both sexes share the same fearfulness traits. <i>Physiology and Behavior</i> , <b>2003</b> , 78, 723-32	3.5	77
49	One-trial tolerance to the effects of chlordiazepoxide on the elevated plus maze may be due to locomotor habituation, not repeated drug exposure. <i>Psychopharmacology</i> , <b>1994</b> , 113, 570-2	4.7	76
48	The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. <i>Behavioural Brain Research</i> , <b>1993</b> , 57, 143-53	3.4	74

47	A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies. <i>Neuropsychopharmacology</i> , <b>2016</b> , 41, 1803-12	8.7	64
46	A quantitative trait locus influencing anxiety in the laboratory rat. <i>Genome Research</i> , <b>2002</b> , 12, 618-26	9.7	64
45	Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding site. <i>Journal of Medicinal Chemistry</i> , <b>2004</b> , 47, 3642-57	8.3	61
44	Learned fear, emotional reactivity and fear of heights: a factor analytic map from a large F(2) intercross of Roman rat strains. <i>Brain Research Bulletin</i> , <b>2002</b> , 57, 17-26	3.9	59
43	Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2010</b> , 332, 4-16	4.7	58
42	In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2009</b> , 329, 170-81	4.7	55
41	Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1159-67	4.6	50
40	Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1199-206	4.6	47
39	7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models. <i>Journal of Medicinal Chemistry</i> , <b>2005</b> , 48, 7089-92	8.3	46
38	The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vivo. <i>Life Sciences</i> , <b>1993</b> , 52, 489-95	6.8	43
37	Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands. <i>Journal of Psychopharmacology</i> , <b>2007</b> , 21, 384-91	4.6	42
36	Scopolamine disrupts hippocampal activity during allocentric spatial memory in humans: an fMRI study using a virtual reality analogue of the Morris Water Maze. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1256-65	4.6	39
35	Development of subtype selective GABAA modulators. <i>CNS Spectrums</i> , <b>2005</b> , 10, 21-7	1.8	39
34	Role of GABAA alpha5-containing receptors in ethanol reward: the effects of targeted gene deletion, and a selective inverse agonist. <i>European Journal of Pharmacology</i> , <b>2005</b> , 526, 240-50	5.3	33
33	A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-center double-blind placebo-controlled study. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 469-81	1.2	32
32	Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. <i>Psychopharmacology</i> , <b>2013</b> , 227, 331-45	4.7	30
31	Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD). <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1192-8	4.6	30
30	Subtype-selective GABAergic drugs facilitate extinction of mouse operant behaviour. <i>Neuropharmacology</i> , <b>2004</b> , 46, 171-8	5.5	30

29	6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of GABA-A alpha5 receptor inverse agonists. <i>Journal of Medicinal Chemistry</i> , <b>2002</b> , 45, 1176-9	8.3	26
28	Genetic mapping of variation in spatial learning in the mouse. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 2426-336.6		24
27	Effects of drugs that potentiate GABA on extinction of positively-reinforced operant behaviour. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2004</b> , 28, 229-38	9	24
26	Anxiolytic-like action of diazepam: which GABA(A) receptor subtype is involved?. <i>Trends in Pharmacological Sciences</i> , <b>2001</b> , 22, 402-3	13.2	24
25	Predicting treatment response to antidepressant medication using early changes in emotional processing. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, 66-75	1.2	24
24	Contribution of GABA(A) receptors containing $\beta$ subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys. <i>Psychopharmacology</i> , <b>2011</b> , 215, 311-9	4.7	22
23	Rat pharmacokinetics and pharmacodynamics of a sustained release formulation of the GABAA alpha5-selective compound L-655,708. <i>Drug Metabolism and Disposition</i> , <b>2006</b> , 34, 887-93	4	21
22	The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial. <i>Trials</i> , <b>2017</b> , 18, 558	2.8	20
21	Reinforcing effects of compounds lacking intrinsic efficacy at $\alpha$ subunit-containing GABAA receptor subtypes in midazolam- but not cocaine-experienced rhesus monkeys. <i>Neuropsychopharmacology</i> , <b>2013</b> , 38, 1006-14	8.7	16
20	The in vivo properties of pagoclonide in rat are most likely mediated by 5Hydroxy pagoclonide. <i>Neuropharmacology</i> , <b>2006</b> , 50, 677-89	5.5	16
19	The GABA-A beta3 subunit mediates anaesthesia induced by etomidate. <i>NeuroReport</i> , <b>2004</b> , 15, 1653-6	1.7	16
18	Overview of the clinical implementation of a study exploring social withdrawal in patients with schizophrenia and Alzheimer's disease. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2019</b> , 97, 87-93	9	15
17	Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABA Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2018</b> , 366, 145-157	4.7	13
16	Validation of experimental medicine methods in psychiatry: the P1vital approach and experience. <i>Biochemical Pharmacology</i> , <b>2011</b> , 81, 1435-41	6	11
15	Discriminative stimulus effects of L-838,417 (7-tert-butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine) on the role of GABA(A) receptor subtypes. <i>Neuropharmacology</i> , <b>2010</b> , 58, 357-64	9.7	11
14	Effects of reinforcement schedule on facilitation of operant extinction by chlordiazepoxide. <i>Journal of the Experimental Analysis of Behavior</i> , <b>2005</b> , 84, 327-38	2.1	11
13	The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): an open-label, randomised controlled trial. <i>Neuropsychopharmacology</i> , <b>2021</b> , 46, 1307-1314	8.7	11
12	Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 135-45	4.6	10

11	The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates. <i>British Journal of Pharmacology</i> , <b>2009</b> , 157, 796-803	8.6	10
10	The proconvulsant effects of the GABAA alpha5 subtype-selective compound RY-080 may not be alpha5-mediated. <i>European Journal of Pharmacology</i> , <b>2006</b> , 548, 77-82	5.3	9
9	From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease. <i>Cell</i> , <b>2021</b> , 184, 5886-5901.e22	56.2	8
8	Effect of disease related biases on the subjective assessment of social functioning in Alzheimer's disease and schizophrenia patients. <i>Journal of Psychiatric Research</i> , <b>2020</b> , 145, 302-302	5.2	2
7	Experimental Medicine in Psychiatry New Approaches in Schizophrenia, Depression and Cognition. <i>Current Topics in Behavioral Neurosciences</i> , <b>2016</b> , 28, 475-97	3.4	2
6	Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , <b>2021</b> , 1-14	3.8	2
5	Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 35, 1473-1478	4.6	1
4	A strategy to home-in on polygenes influencing susceptibility to anxiety. <i>Human Psychopharmacology</i> , <b>1999</b> , 14, S3-S10	2.3	0
3	Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2022</b> , 113, 110463	5.5	0
2	Cross-disorder and disorder-specific deficits in social functioning among schizophrenia and Alzheimer's disease patients.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0263769	3.7	0
1	Validation of the P1vital <sup>2</sup> Faces Set for Use as Stimuli in Tests of Facial Emotion Recognition.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 663763	5	